Pharmaceutical Giant GSK & Pfizer $35 Billion Spinoff Haleon IPO on London Exchange, Consumer Giant & Maker of Panadol Painkillers & Sensodyne Toothpaste
21st July 2022 | Hong Kong
Pharmaceutical giant GSK $35 billion spinoff Haleon has IPO on London Exchange (GBP 330 pence, 18/7/2022) with a market value of around $33 billion (21/7/22). The demerger from GSK was announced on 23rd June 2022: “It is proposed that the separation will be effected by way of a demerger of at least 80%. of GSK’s 68%. holding in the Consumer Healthcare business to GSK shareholders. The Consumer Healthcare business is currently a joint venture between GSK and Pfizer Inc (“Pfizer”), with GSK holding a majority controlling interest of 68%. and Pfizer holding 32 %. Haleon is the global leader on consumer healthcare with popular products including Panadol Painkillers & Sensodyne Toothpaste, and with full range of products covering oral, respiratory and digestive health, pain relief and vitamins, minerals and supplements.
“ Pharmaceutical Giant GSK & Pfizer $35 Billion Spinoff Haleon IPO on London Exchange, Consumer Giant & Maker of Panadol Painkillers & Sensodyne Toothpaste “
Haleon will be a global leader in consumer healthcare with a focused strategy to deliver sustainable above-market growth and attractive returns to shareholders; a world-class portfolio of category-leading brands; an attractive geographic footprint well placed for growth; competitive capabilities including strong route-to-market capabilities across all channels; and brand building and innovation capabilities alongside digital connectivity, which offers a proposition that combines human understanding with trusted science.
Haleon’s product portfolio is split among five categories: Oral Health, Pain Relief, VMS, Respiratory Health, Digestive Health and Other. Haleon’s largest category by revenue is Oral Health, which accounted for 28.5 per cent. of Haleon’s revenue in the year ended 31 December 2021. The Pain Relief and Digestive Health and Other categories also significantly contribute to revenue, respectively contributing 23.4 per cent. and 20.4 per cent. of revenue in the year ended 31 December 2021. VMS and Respiratory Health respectively accounted for 15.7 per cent. and 11.9 per cent. of revenue in the year ended 31 December 2021.
In the year ended 31 December 2021 the profit before tax attributable to Haleon was £1,636 million. As at 31 March 2022 the gross assets of Haleon were £45,023 million. On an unaudited pro forma basis, net debt of Haleon as at 31 March 2022 would have been £10,349 million.